Frontiers in Pharmacology · Nov 16, 2026

The Role and Status of Atorvastatin in the Cholesterol and Inflammation Dual-Target Era: A narrative review

By Hui-Hui Liu, Sha Li, Jian-Jun Li

The burden of atherosclerotic cardiovascular disease (ASCVD) continues to rise, posing a serious threat to global health. Low-density lipoprotein cholesterol (LDL-C), as the primary risk factor for atherosclerosis, has been a key target in ASCVD prevention and treatment. However, many patients, despite achieving target LDL-C levels following standardized treatment, still face significant residual cardiovascular risk, suggesting that lipid-lowering therapy alone cannot fully halt atherosclerosis progression. Abundant studies demonstrate that chronic low-grade inflammation is present throughout atherosclerosis, and anti-inflammatory therapy can independently reduce the risk of cardiovascular events, giving rise to the cholesterol-inflammation fusion hypothesis. Today, ASCVD management has undergone a fundamental shift, moving from lipid-lowering to a dual-target era of lipid-lowering and anti-inflammation. Statins combine lipid-lowering and anti-inflammatory effects, with proven cardiovascular benefits; they remain the cornerstone of ASCVD management in the dual-target era. Atorvastatin exhibits several notable features: a titratable dosing strategy that spans all risk categories, robust LDL-C lowering, and substantial suppression of inflammatory mediators, including C-reactive protein, interleukin-6, and tumor necrosis factor-α. Its distinctive pentasubstituted pyrrole structure confers high lipophilicity, which may contribute to its lipid‑lowering activity. In addition, its active metabolites exert not only lipid‑modulating effects but also marked anti‑inflammatory and antioxidant properties. Multiple large trials have shown that atorvastatin achieves concurrent control of lipids and inflammation, accompanied by reductions in cardiovascular events. Taken together, the available evidence supports the combined lipid-lowering and anti-inflammatory effects of atorvastatin across diverse patient populations, making it a well-validated option for the management of ASCVD.

The paperJournal siteInterventions

AgingResearch.News